Neurofibromatosis Type-2 Pipeline, Clinical Trials, and Emerging Drugs (2023) | Companies – AstraZeneca, Recursion Pharma, Betta Pharma, Novartis Pharma, Genentech, Takeda, and Others

Advertisements

DelveInsight’s report titled “Neurofibromatosis Type-2 Pipeline Insight 2023” offers extensive information on more than 5+ companies and over 5+ pipeline drugs in the field of Neurofibromatosis Type-2 research. The Neurofibromatosis Type-2 pipeline report encompasses detailed profiles of the pipeline drugs for Neurofibromatosis Type-2, including information on Neurofibromatosis Type-2 clinical trials and nonclinical stage products. It also provides a comprehensive assessment of the therapeutics based on product type, stage, route of administration, and molecule type. Additionally, the report highlights the inactive pipeline products in this domain.

 

For the Neurofibromatosis Type-2 emerging drugs, the pipeline analysis report presents a comprehensive view of the therapeutic landscape, considering the development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The research on the Neurofibromatosis Type-2 pipeline covers various aspects such as business opportunities, challenges, potential partnerships, strong competitors, and growth strategies. It provides a detailed description of each drug, including its mechanism of action, Neurofibromatosis Type-2 clinical trial studies conducted for Neurofibromatosis Type-2, any NDA approvals obtained for Neurofibromatosis Type-2, and the product development activities encompassing technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant details.

 

To explore more information on the latest breakthroughs in the Neurofibromatosis Type-2 Pipeline treatment landscape of the report, click here @ Neurofibromatosis Type-2 Pipeline Outlook

 

Key Takeaways from the Neurofibromatosis Type-2 Pipeline Report

DelveInsight’s Neurofibromatosis Type-2 Pipeline analysis depicts a robust space with 5+ active players working to develop 5+ pipeline treatment therapies.
The leading Neurofibromatosis Type-2 Companies are working in the market include AstraZeneca, Recursion Pharma, Betta Pharma, Novartis Pharma, Genentech, Takeda, and others
Emerging Neurofibromatosis Type-2 Pipeline Therapies in the various stages of development include REC-2282, Icotinib, Endostatin, RAD001, Everolimus, Bevacizumab, Lapatinib, Everolimus (RAD001), Multichannel Auditory Brain Stem Implant, AZD2014, Selumetinib, and others
On February, 2023, Novartis Pharmaceuticals announced a drug name of RAD001, everolimus. The purpose of the study is to determine if RAD001 treatment will shrink or slow the growth of the vestibular schwannoma(s) in Neurofibromatosis 2 (NF2) patients. Secondary objectives include determining if RAD001 treatment will improve hearing ability in NF2 patients.
On March, 2023, Recursion Pharmaceuticals announced a drug name of REC-2282. This is a parallel-group, two-staged, Phase 2/3, randomized, multi-center study to investigate the efficacy and safety of REC-2282 in patients with progressive NF2 mutated meningiomas.

 

Neurofibromatosis Type-2 Overview

Neurofibromatosis 2 (NF2) is a rare genetic disorder that is primarily characterized by noncancerous (benign) tumors of the nerves that transmit balance and sound impulses from the inner ears to the brain (bilateral acoustic neuromas/vestibular schwannomas). Symptoms may become apparent during childhood, adolescence, and early adulthood or later in adult life.

 

For further information, refer to the detailed Neurofibromatosis Type-2 Unmet Needs, Neurofibromatosis Type-2 Market Drivers, and Market Barriers, click here for Neurofibromatosis Type-2 Ongoing Clinical Trial Analysis

 

Neurofibromatosis Type-2 Emerging Drugs Profile

Selumetinib: AstraZeneca
REC-2282: Recursion Pharmaceuticals

 

Neurofibromatosis Type-2 Pipeline Therapeutics Assessment

There are approx. 5+ Neurofibromatosis Type-2 companies which are developing the therapies for Neurofibromatosis Type 2. The Neurofibromatosis Type-2 companies which have their Neurofibromatosis Type 2 drug candidates in the most advanced stage, i.e. phase II include, AstraZeneca.

 

Request a sample and discover the recent advances in Neurofibromatosis Type-2 Ongoing Clinical Trial Analysis and Medications, click here @ Neurofibromatosis Type-2 Treatment Landscape

 

Neurofibromatosis Type-2 Therapeutics Assessment

Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type

 

Some of the Companies in the Neurofibromatosis Type-2 Therapeutics Market include-

AstraZeneca, Recursion Pharma, Betta Pharma, Novartis Pharma, Genentech, Takeda, and others.

 

Dive deep into rich insights for drugs for Neurofibromatosis Type-2 Pipeline, click here @ Neurofibromatosis Type-2 Unmet Needs and Analyst Views

 

Scope of the Neurofibromatosis Type-2 Pipeline Report

Coverage- Global
Neurofibromatosis Type-2 Companies- AstraZeneca, Recursion Pharma, Betta Pharma, Novartis Pharma, Genentech, Takeda, and others.
Neurofibromatosis Type-2 Therapies- REC-2282, Icotinib, Endostatin, RAD001, Everolimus, Bevacizumab, Lapatinib, Everolimus (RAD001), Multichannel Auditory Brain Stem Implant, AZD2014, Selumetinib, and others
Neurofibromatosis Type-2 Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Neurofibromatosis Type-2 Mergers and acquisitions, Neurofibromatosis Type-2 Licensing Activities @ Neurofibromatosis Type-2 Emerging Drugs, and Recent Trends

 

Table of Content

Introduction
Neurofibromatosis Type-2 Executive Summary
Neurofibromatosis Type 2: Overview
Neurofibromatosis Type-2 Pipeline Therapeutics
Neurofibromatosis Type-2 Therapeutic Assessment
Neurofibromatosis Type 2 – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Drug name: Company name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Selumetinib: AstraZeneca
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Drug name: Company name
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Neurofibromatosis Type 2 Key Companies
Neurofibromatosis Type 2 Key Products
Neurofibromatosis Type 2- Unmet Needs
Neurofibromatosis Type 2- Market Drivers and Barriers
Neurofibromatosis Type 2- Future Perspectives and Conclusion
Neurofibromatosis Type 2 Analyst Views
Neurofibromatosis Type 2 Key Companies
Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.

Advertisements

Smart public opinion research for everyone.

%d bloggers like this: